South Florida Bone Marrow/Stem Cell Transplant Institute Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2009
NCT00900497
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Dipnarine Maharaj | Medical Director, South Florida Bone Marrow / Stem Cell Transplant Institute | South Florida Bone Marrow/Stem Cell Transplant Institute

Active Ingredients

Drugs in Phase 2 Trials (2)

granulocytes (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Frailty (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2